Skip to content

Tectonic Therapeutics TECX Operating lease right-of-use asset amortization

Operating lease right-of-use asset amortization at other companies

Ginkgo Bioworks logo
Ginkgo BioworksDNA
Ethos Technologies, Inc.
 logo
Ethos Technologies, Inc. LIFE

Other financials

Income statement

See full
Operating income-$27.3M-49.2%
Net income-$25.2M-58.7%
EPS (diluted)-$1.34-44.1%

Balance sheet

See full
Cash & equivalents$236.9M-22.8%
Total debt$4.9M+86.1%
Total equity$230.4M-23.5%
Total assets$246.6M-21.7%

Cash flow

See full
Operating cash flow-$18.4M-40.7%
CapEx$19.0K-29.6%
Free cash flow-$18.4M-40.6%

Valuation

See full
Market cap$585.51M+58.3%
Enterprise value$353.51M+438%

Returns & leverage

See full
Return on equity-31.4%
Debt / equity0.0×
Current ratio18.5×-4.4×

Where this comes from

Reported directly by Tectonic Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense.

The official record: Tectonic Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Tectonic Therapeutics's operating lease right-of-use asset amortization.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Tectonic Therapeutics's operating lease right-of-use asset amortization?
Tectonic Therapeutics (TECX) reported operating lease right-of-use asset amortization of $496K in Q1 2026.
How has Tectonic Therapeutics's operating lease right-of-use asset amortization changed year-over-year?
Tectonic Therapeutics's operating lease right-of-use asset amortization decreased by 2.9% year-over-year, from $511K to $496K.